If you’re leaving one compounded-GLP-1 provider for another, the safe switch is decided on supervision and transparency — not price or speed — because in March 2026 the FDA issued 30 warning letters to telehealth sites for marketing compounded GLP-1s as “the same as” FDA-approved drugs and for hiding which pharmacy actually made them. Compounded medications are not FDA-reviewed for safety, effectiveness, or quality (FDA / Pharmaceutical Technology, 2026). That doesn’t make every compounded program unsafe — but it does mean the burden is on the provider to prove it operates responsibly, and on you to know what to check.
This is a practical checklist for switching. It won’t tell you which brand to pick. It will tell you the questions a trustworthy provider answers without hesitation — and the answers that should send you elsewhere.
What actually happened with the FDA warning letters?
On March 3, 2026, the FDA sent 30 warning letters to telehealth organizations marketing compounded GLP-1s (Pharmaceutical Technology). Two practices drew the most scrutiny:
- “Sameness” claims — marketing that implied the compounded product was identical to an FDA-approved drug like Ozempic or Zepbound. It isn’t. Compounded versions are not the branded product and are not FDA-reviewed.
- Obscured sourcing — advertising the drug under the telehealth company’s own brand “without clarifying that the firm is not the actual compounder.”
FDA Commissioner Marty Makary framed the agency’s position directly: compounded drugs can matter for genuine shortages or specific patient needs, “but compounders should not try to compound drugs in a way that circumvents FDA’s approval process.” The letters weren’t a ban on compounded GLP-1s — they were a signal about how they’re being marketed and sold. That distinction is exactly what you’re screening for when you switch.
Why are people switching in the first place?
Two forces are pushing patients to shop. The regulatory picture around large-scale GLP-1 compounding tightened after the official drug shortages resolved, which disrupted some programs. And many people on compounded semaglutide or tirzepatide are discovering that losing weight isn’t the same as losing it well — energy, strength, and muscle can suffer if no one is monitoring body composition. If that’s your situation, our pieces on preventing muscle loss on a GLP-1 and GLP-1 fatigue are worth reading alongside this one. The point of switching shouldn’t just be to keep the prescription flowing — it should be to move to a program that actually supervises the outcome.
The switch checklist: what a legitimate provider answers plainly
Use these as direct questions. A responsible provider answers each one without deflecting.
| Check | What “good” looks like | Red flag |
|---|---|---|
| Named pharmacy | Names the specific licensed compounding pharmacy and its state | Won’t name the pharmacy; hides it behind house branding |
| Honest labeling | States clearly that the product is compounded and not FDA-approved | Claims it’s “the same as” Ozempic / Zepbound |
| Licensed clinician | A clinician reviews your history and can adjust, monitor, or decline | Intake form auto-ships a fixed dose with no real review |
| Monitoring plan | Baseline and follow-up labs; a plan to track how you’re responding | ”Set and forget” refills, no check-ins |
| Dose transparency | Tells you the exact molecule, concentration, and dose | Vague “proprietary blend” language |
| Pricing terms | Transparent price, no lock-in contract | Long contracts, hard-to-cancel auto-renew |
| Body-composition awareness | Talks about protecting muscle, not just dropping weight | Only tracks the scale |
If a provider clears every row, you’re looking at a supervised medical program. If it stumbles on the first three, you’re looking at a storefront — the kind the FDA’s letters were aimed at.
Why does the “named pharmacy” question matter so much?
Because it’s the fastest test of whether you’re in a clinical relationship or a transaction. Compounded medications come from state-licensed 503A pharmacies (patient-specific) or larger 503B outsourcing facilities, both of which are traceable and accountable. A provider that will tell you which pharmacy prepares your medication, and in what state it’s licensed, is one that expects to be held responsible for quality. Not naming it was precisely one of the behaviors the FDA cited. Our deeper guide, how to tell if an online longevity clinic is safe and legitimate, expands this into a full 7-point vetting process.
What does “supervised” actually buy you?
The core difference between a fulfillment site and a clinical program is who is accountable when something changes. A supervised program — like our medically supervised GLP-1 program — has a licensed clinician who can raise or lower your dose based on how you’re responding, pause it if side effects appear, monitor labs and body composition, and — importantly — decline to prescribe when it isn’t appropriate. A clinician who can say no is a feature, not a bug: it’s the clearest evidence that a real person, not an order-fulfillment flow, stands behind your prescription.
Compounded GLP-1 medications are prepared by state-licensed, FDA-regulated compounding pharmacies and are not FDA-approved as finished products; they are not reviewed by the FDA for safety, effectiveness, or quality. Use is decided within a licensed clinical relationship, based on your own history and labs. This is educational information, not medical advice or a promise of results.
Switching compounded GLP-1 providers FAQ
Why did the FDA send warning letters about compounded GLP-1s? On March 3, 2026, the FDA issued 30 warning letters to telehealth organizations marketing compounded GLP-1s. The main issues were marketing that implied the compounded products were identical to FDA-approved drugs like Ozempic or Zepbound, and advertising drugs under the company’s own brand without disclosing that a separate pharmacy was the actual compounder.
Are compounded GLP-1s FDA-approved? No. Compounded medications are not FDA-approved finished products and are not reviewed by the FDA for safety, effectiveness, or quality. They are prepared by state-licensed compounding pharmacies for specific patient needs. A legitimate provider states this clearly rather than implying the product is the same as the branded drug.
What should I check before switching GLP-1 providers? Confirm the named licensed compounding pharmacy and its state, a licensed clinician who reviews your history and can adjust or decline, honest labeling (no “identical to Ozempic” claims), a real monitoring plan, and transparent pricing without lock-in contracts. If any of those can’t be answered, treat it as a warning sign.
Is it safe to buy GLP-1s from a site that won’t name its pharmacy? That’s a significant red flag. Not naming the compounding pharmacy was one of the practices the FDA cited in its 2026 warning letters. A provider you can trust will tell you which licensed pharmacy prepares your medication and in what state it is licensed.
Should I switch providers just for a lower price? Price alone is a poor basis for a medication decision. The safer comparison weighs clinician oversight, pharmacy transparency, monitoring, and honest labeling alongside cost. A cheaper program that skips supervision can cost more in risk than it saves in dollars.
A supervised program starts with your labs and a clinician who can adjust or decline. Find Your Treatment →
Sources
- Pharmaceutical Technology — Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s (March 3, 2026): https://www.pharmtech.com/view/why-the-fda-issued-30-warning-letters-to-telehealth-sites-marketing-compounded-glp-1s
- Venable LLP — FDA’s Latest GLP-1 Crackdown: What Compounders and Telehealth Platforms Need to Know (2026): https://www.venable.com/insights/publications/2026/03/fdas-latest-glp-1-crackdown-what-compounders
- Sheppard Mullin — FDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters (2026): https://www.sheppard.com/insights/blogs/fdas-focus-returns-to-compounding-and-telehealth-another-wave-of-warning-letters